Stemline Therapeutics (STML) Stock Price, News & Analysis

Company Overview

Stemline Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and internationally. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older. It also developing CD123 that is in Phase I/II clinical trials for the treatment of chronic myelomonocytic leukemia and myelofibrosis, as well as acute myeloid leukemia and multiple myeloma in combination with other therapies. In addition, the company is developing SL-801, a novel oral small molecule reversible inhibitor of nuclear transport protein, which is in Phase I clinical trial for the treatment of solid and hematologic cancers; and SL-701, an immunotherapy that has completed Phase II clinical trials to treat brain cancer. Its preclinical pipeline products include SL-501, a CD123 targeted therapy; SL- 1001, an oral, selective small molecule RET kinase inhibitor targeting multiple oncology indications; and SL-901, a small molecule kinase inhibitor. Stemline Therapeutics, Inc. was founded in 2003 and is based in New York, New York.

Key Stats

• Today's Range: $11.83 to $11.83
• 50-Day Range: $11.83 to $11.83
• 52-Week Range: $3.21 to $18.22
• Volume: 1,084 shs
• Average Volume: 1.52 million shs
• Market Capitalization: $621.21 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

STML Stock Analysis - Frequently Asked Questions

How were Stemline Therapeutics' earnings last quarter?

Stemline Therapeutics Inc (NASDAQ:STML) posted its earnings results on Thursday, November, 7th. The biopharmaceutical company reported ($0.34) EPS for the quarter, topping analysts' consensus estimates of ($0.42) by $0.08. The biopharmaceutical company earned $13.33 million during the quarter, compared to analysts' expectations of $13.40 million. Stemline Therapeutics had a negative net margin of 150.30% and a negative trailing twelve-month return on equity of 48.14%.

What other stocks do shareholders of Stemline Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Stemline Therapeutics investors own include TG Therapeutics (TGTX), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Exelixis (EXEL), Sorrento Therapeutics (SRNE) and ZIOPHARM Oncology (ZIOP).

Company Calendar

• Last Earnings: 11/07/2019
• Today: 8/24/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:STML
• CIK: 1264587
• Web: www.stemline.com
• Phone: 646-502-2311
• Fax: N/A
• Employees: 92
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($1.83)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$76.82 million
• Net Margins: -150.30%
• Pretax Margin: N/A
• Return on Equity: -48.14%
• Return on Assets: -41.35%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.43
• Quick Ratio: 7.37

Sales & Book Value

• Annual Sales: $43.22 million
• Price / Sales: 14.37
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.26 per share
• Price / Book: 3.63

Miscellaneous

• Outstanding Shares: 52,511,000
• Free Float: N/A
• Market Cap: $621.21 million
• Optionable: Optionable
• Beta: 1.78